Key Points
- CEO Xingjuan Chao sold 100,000 shares across three trades (Nov. 21, Dec. 1 and Dec. 4) for about $1.64 million total; after the latest 25,000‑share sale at $18.82 she directly owns 798,135 shares, a roughly 3.04% reduction.
- CeriBell shares opened at $20.22 (52‑week range $10.01–$32.75) and the company posts negative earnings metrics, while analysts hold a "Moderate Buy" consensus with a $25.17 average target amid mixed price‑target revisions.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $18.82, for a total transaction of $470,500.00. Following the sale, the chief executive officer directly owned 798,135 shares of the company's stock, valued at $15,020,900.70. This represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Xingjuan Chao also recently made the following trade(s):
- On Monday, December 1st, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $16.59, for a total transaction of $414,750.00.
- On Friday, November 21st, Xingjuan Chao sold 50,000 shares of CeriBell stock. The stock was sold at an average price of $15.13, for a total value of $756,500.00.
CeriBell Stock Performance
Shares of CBLL opened at $20.22 on Tuesday. The company's 50 day moving average price is $13.61 and its 200 day moving average price is $14.39. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75. The company has a market capitalization of $750.16 million, a PE ratio of -13.39 and a beta of 1.30.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The business had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. Research analysts expect that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.
Hedge Funds Weigh In On CeriBell
Several institutional investors have recently added to or reduced their stakes in CBLL. Deutsche Bank AG boosted its position in CeriBell by 0.4% in the first quarter. Deutsche Bank AG now owns 231,629 shares of the company's stock valued at $4,450,000 after buying an additional 842 shares in the last quarter. Swiss National Bank acquired a new stake in shares of CeriBell during the first quarter worth approximately $467,000. Nuveen LLC bought a new position in shares of CeriBell in the first quarter valued at approximately $311,000. Lord Abbett & CO. LLC boosted its holdings in shares of CeriBell by 7.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock worth $6,138,000 after acquiring an additional 23,451 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in CeriBell during the 1st quarter worth approximately $175,000.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating for the company in a research note on Wednesday, November 5th. TD Cowen dropped their price target on CeriBell from $36.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, November 5th. Raymond James Financial assumed coverage on shares of CeriBell in a report on Tuesday, October 21st. They set a "strong-buy" rating and a $19.00 price objective on the stock. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of CeriBell in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $25.17.
View Our Latest Stock Analysis on CBLL
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
